Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies
A diverse range of drug resistance mechanisms in cancer cells and their microenvironment
significantly reduces the effectiveness of anti-cancer therapies. Growing evidence suggests
that transcriptional effectors of the Hippo pathway, YAP and TAZ, promote resistance to
various anti-cancer therapies, including cytotoxic chemotherapy, molecular targeted therapy,
and radiation therapy. Here, we overview the role of YAP and TAZ as drug resistance
mediators, and also discuss potential upstream regulators and downstream targets of …
significantly reduces the effectiveness of anti-cancer therapies. Growing evidence suggests
that transcriptional effectors of the Hippo pathway, YAP and TAZ, promote resistance to
various anti-cancer therapies, including cytotoxic chemotherapy, molecular targeted therapy,
and radiation therapy. Here, we overview the role of YAP and TAZ as drug resistance
mediators, and also discuss potential upstream regulators and downstream targets of …
Abstract
A diverse range of drug resistance mechanisms in cancer cells and their microenvironment significantly reduces the effectiveness of anti-cancer therapies. Growing evidence suggests that transcriptional effectors of the Hippo pathway, YAP and TAZ, promote resistance to various anti-cancer therapies, including cytotoxic chemotherapy, molecular targeted therapy, and radiation therapy. Here, we overview the role of YAP and TAZ as drug resistance mediators, and also discuss potential upstream regulators and downstream targets of YAP/TAZ in cancer. The widespread involvement of YAP and TAZ in resistance mechanisms suggests that therapeutic targeting of YAP and TAZ may expedite the development of effective anti-resistance therapies.
Springer
